Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 13/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 3/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 3/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 2/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20534861 | 0.82 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL20535237 | 0.81 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL20534826 | 0.81 | HDAC6 (0.73) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL6358690 | 0.80 | KMT2A (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL20535023 | 0.78 | HDAC6 (0.68) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL20535159 | 0.77 | HDAC6 (0.67) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL20535240 | 0.77 | HDAC6 (0.71) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL20534763 | 0.76 | HDAC6 (0.78) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL20534624 | 0.76 | HDAC6 (0.78) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL23317090 | 0.75 | HDAC6 (0.75) | HDAC6HDAC1HDAC8HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720316-A2 | NON-VIRAL CELL ENGINEERING | Arsenal Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20250011878-A1 | METHOD TO DETECT RNA BIOMARKERS | ITALFARMACO SPA (IT) | 2025-01-09 | — | — | US | claimed |
| WO-2024259376-A2 | NON-VIRAL CELL ENGINEERING | ARSENAL BIOSCIENCES, INC. (US) | 2024-12-19 | — | — | WO | claimed |
| EP-4437138-A1 | METHOD TO DETECT RNA BIOMARKERS | Italfarmaco SpA (IT) | 2024-10-02 | — | — | EP | claimed |
| US-20240207228-A1 | A COMBINATION COMPRISING A SPECIFIC HDAC6 INHIBITOR AND AT LEAST ONE CTLA4 CHECKPOINT INHIBITOR | ITALFARMACO SPA (IT) | 2024-06-27 | — | — | US | claimed |
| CN-118202068-A | Method for detecting RNA biomarker | 意大发马克股份公司 | 2024-06-14 | — | — | CN | claimed |
| EP-4326259-A1 | A COMBINATION COMPRISING A SPECIFIC HDAC6 INHIBITOR AND AT LEAST ONE CTLA4 CHECKPOINT INHIBITOR | Italfarmaco SpA (IT) | 2024-02-28 | — | — | EP | claimed |
| CN-117177745-A | Combination comprising a specific HDAC6 inhibitor and at least one CTLA4 checkpoint inhibitor | 意大发马克股份公司 | 2023-12-05 | — | — | CN | claimed |
| WO-2023094365-A1 | METHOD TO DETECT RNA BIOMARKERS | ITALFARMACO S.P.A. (IT) | 2023-06-01 | — | — | WO | claimed |
| CN-110546140-B | Selective HDAC6 inhibitors | 意大发马克股份公司 | 2023-05-16 | — | — | CN | claimed |
| EP-3562810-B1 | BENZHYDROXAMIC ACID DERIVATIVES AS SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-05-03 | — | — | EP | claimed |
| WO-2022223543-A1 | A COMBINATION COMPRISING A SPECIFIC HDAC6 INHIBITOR AND AT LEAST ONE CTLA4 CHECKPOINT INHIBITOR | ITALFARMACO S.P.A. (IT) | 2022-10-27 | — | — | WO | claimed |
| US-11351178-B2 | Selective HDAC6 inhibitors | ITALFARMACO SPA (IT) | 2022-06-07 | — | — | US | claimed |
| US-20210128577-A1 | Selective HDAC6 Inhibitors | ITALFARMACO S.P.A. (IT) | 2021-05-06 | — | — | US | claimed |
| EP-3562810-A1 | SELECTIVE HDAC6 INHIBITORS | Italfarmaco SpA (IT) | 2019-11-06 | — | — | EP | claimed |
| WO-2018189340-A1 | SELECTIVE HDAC6 INHIBITORS | ITALFARMACO S.P.A. (IT) | 2018-10-18 | — | — | WO | claimed |
| EP-4720316-A2 | NON-VIRAL CELL ENGINEERING | Arsenal Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025217371-A2 | MULTIFUNCTIONAL MOLECULES BINDING TO TCR AND USES THEREOF | MARENGO THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-3562810-A1 | SELECTIVE HDAC6 INHIBITORS | Italfarmaco SpA (IT) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018189340-A1 | SELECTIVE HDAC6 INHIBITORS | ITALFARMACO S.P.A. (IT) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128577-A1 | Selective HDAC6 Inhibitors | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885HDAC8 10/4885 |
| US-11351178-B2 | Selective HDAC6 inhibitors | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885HDAC8 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.